Table 1:
Baseline Clinical and Treatment Characteristics.
| Parameter | All (N=1167) n (%) |
|---|---|
| Gender | |
| Male | 660 (57) |
| Female | 507 (43) |
| Age at autoHCT (years) | |
| Median (Range) | 61.4 (25.4-82.3) |
| Age at autoHCT | |
| ≤ 70 years | 1021 (87) |
| > 70 years | 146 (13) |
| Race | |
| Black | 234 (20) |
| Non-black | 919 (79) |
| Unknown | 14 (1) |
| Light chain type | |
| Kappa | 766 (66) |
| Lambda | 391 (34) |
| Biclonal | 3 (<1) |
| Unknown | 7 (1) |
| High-risk chromosomal abnormality ¥ | |
| No | 880 (75) |
| Yes | 222 (19) |
| Unknown | 65 (6) |
| R-ISS | |
| I | 331 (28) |
| II | 427 (37) |
| III | 58 (5) |
| Unknown | 351 (30) |
| Bone lesions | |
| None | 214 (18) |
| 1 to 3 | 464 (40) |
| > 3 | 468 (40) |
| Unknown | 21 (2) |
| Induction treatment | |
| VRD | 441 (38) |
| VCD | 160 (14) |
| KRD | 219 (19) |
| VD | 151 (13) |
| ImiD+Dexa | 83 (7) |
| Other | 113 (10) |
| HCT-CI | |
| Median (Range) | 2 (0.0 - 14.0) |
| HCT-CI | |
| ≤ 3 | 897 (77) |
| > 3 | 268 (23) |
| Unknown | 2 (<1) |
| Conditioning regimen | |
| Mel | 993 (85) |
| BuMel based | 125 (11) |
| Mel based (other) | 28 (2) |
| Evomela | 21 (2) |
| Response prior to autoHCT | |
| sCR/CR | 165 (14) |
| VGPR | 531 (46) |
| PR | 449 (38) |
| SD | 22 (2) |
| MRD status prior to autoHCT | |
| Negative | 391 (34) |
| Positive | 505 (43) |
| NA | 271 (23) |
| History of second malignancy before autoHCT | |
| No | 1023 (88) |
| Yes | 141 (12) |
autoHCT=Autologous hematopoietic stem cell transplant, HCT-CI=Hematopoietic Cell Transplantation-specific Comorbidity Index, R-ISS=Revised multiple myeloma international staging system, VRD= Bortezomib /lenalidomide /dexamethasone, VCD=Bortezomib /cyclophosphamide/dexamethasone, KRD= Carfilzomib/lenalidomide/dexamethasone, VD=Bortezomib/dexamethasone, ImiD=Immunomodulatory drugs, Mel=Melphalan, BuMel=Busulfan/Melphalan, sCR=Stringent complete response, CR=Complete response, nCR=Near complete response, VGPR=very good partial response, PR=Partial response, SD=Stable disease, Dexa=dexamethasone, MRD=Minimal residual disease, NA=not available.
Defined as del17p, t(4;14), t(14;16) or 1q21 gain or amplification by fluorescence in situ hybridization (FISH).